Full Breakdown
Intuitive Surgical Q3 2026 Earnings Beat Amid Pricing Cuts and $450 Million Settlement
By Drooid · · How we work
Core Event: Quarterly Results and Immediate Market Reaction
Intuitive Surgical Inc. reported third-quarter FY 2026 revenue of $3.05 billion, a 22 % YoY increase, and adjusted earnings per share of $3.00, beating the consensus estimate of $2.64. GAAP earnings were $1.49 per share, reflecting a $450 million pre-tax charge for a no-fault antitrust class-action settlement. Despite the beat, the stock fell 7 %–8 % in after-hours trading and later slid 10.5 % in extended trading.
Data & Statistics
| Metric | Q3 2026 | Q3 2025 | YoY Change |
|---|---|---|---|
| Revenue | $3.05 billion | $2.51 billion | +22 % |
| Adjusted EPS | $3.00 | $2.40 | +25 % |
| GAAP EPS | $1.49 | $1.95 | –24 % |
| GAAP Net Income | $523 million | $704 million | –26 % |
| Da Vinci placements | 546 (incl. 315 da Vinci 5) | 427 | +28 % |
| Instruments & accessories revenue | $1.80 billion | – | +18 % |
| Systems revenue | $769 million | $590 million | +30 % |
| Worldwide procedures | +15 % YoY (da Vinci +14 %, Ion +31 %) | – | – |
| Cash & investments | $6.80 billion | $8.6 billion (Q2 2026) | –21 % |
| Settlement charge | $450 million (pre-tax) | – | – |
The company’s installed base was reported as 12,094 da Vinci systems (up 12 % YoY) in one source and exceeds 13,200 systems in another, indicating a reporting discrepancy.
Official Statements & Responses
Executives said the settlement “provides a clear framework” for continued collaboration on remanufacturing and servicing.
Verbatim Quotes
- “Our strong performance this quarter was marked by broad-based adoption across our multi-port, single-port, and Ion platforms, with customers using our systems to perform, on average, over 10,000 procedures per day throughout the period,” — Dave Rosa, CEO
- “This no-fault settlement provides a clear framework on how we'll continue to work together in those two specific areas,” — Dave Rosa, CEO
Background & Context
The pricing initiative, first discussed in July, reduces da Vinci instrument and accessory revenue per procedure by 3 %–5 % on a constant-mix basis once fully implemented. Rollout begins in China in Q4 2026, moves to the U.S. in Q1 2027 pending 510(k) clearance, reaches Europe in H2 2027, and is expected to be fully realized by the end of 2027. Management cites the 2020 Extended Use Program as evidence that volume growth can neutralize the margin impact.
The $450 million settlement resolves a class-action lawsuit alleging antitrust concerns over third-party remanufacturing and servicing of da Vinci instruments. The agreement is “no-fault” and awaits court approval next year.
Conflicting Reports & Gaps
- Installed Base: One source lists 12,094 systems, another states it “exceeds 13,200 systems.” The discrepancy is not clarified in filings.
- Procedural Growth Detail: U.S. da Vinci procedure growth is reported at 10 %, the lowest since the pandemic, but drivers are not fully detailed.
What’s Next: Guidance and Implementation Timeline
Intuitive Surgical projects full-year 2026 worldwide da Vinci procedures to grow 14 %–15 %, narrowing the prior range of 13.5 %–15.5 %. Gross profit margin is expected at 68.7 %–69.3 %, and non-GAAP operating expense growth at 11 %–13 %. The company anticipates the pricing headwind will be fully absorbed by the end of 2027, with volume elasticity and higher-margin SP instruments offsetting the reduction. Court approval of the settlement is anticipated next year, after which the firm will focus on safety, quality, and security enhancements for its robotic platforms.
